ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Fred Saad presented a multi-institutional, exploratory analysis to evaluate the effect of prior endocrine therapy on clinical benefit of abiraterone (AA) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) in the randomized phase III study, COU-AA-302. A total of 1 088 patients who received continuous gonadotropin-releasing hormone [GnRH] agonists were randomized 1:1 to AA (1 g) + prednisone (P) (5 mg BID) or placebo + P. Radiographic progression-free survival (rPFS) and OS were “co-primary” end points of this trial. The rPFS was defined as time to first occurrence of bone scan, CT, or MRI progression, or death, whichever came first. They compared the treatment effect of AA on rPFS (investigator review at 55% of OS events) for subgroups above or below the median duration of prior endocrine therapy in 2 categories: prior GnRH agonists and androgen receptor (AR) inhibitors. Cox model was used to obtain the hazard ratio (HR) and associated 95% confidence interval (CI) with statistical inference by log rank statistic.

auaAccording to Dr. Saad, irrespective of median duration of prior GnRH agonist or AR inhibitor therapy, rPFS was significantly more favorable with AA + P than placebo + P. Moreover, increased median rPFS was evident in patients who had longer prior exposure to GnRH agonists or AR inhibitors, as compared to both AA + P and placebo + P treatment groups.

Abiraterone is a specific CYP17 inhibitor, and with prednisone, randomized clinical trials have shown that it can have significant improvement in rPFS in chemotherapy-naïve, asymptomatic or mildly symptomatic men who have progressive mCRPC. In this exploratory analysis, clinical benefit with AA + P vs placebo + P was demonstrated by significantly improved rPFS, regardless of whether men had exposure to prior endocrine therapy above or below the median duration of 37 and 16 months for GnRH agonists or AR inhibitors, respectively. Prior GnRH agonist and anti-androgen treatment duration should be further studied in order to fully assess their impact.

Click HERE to view the poster from this session

Presented by Fred Saad, MD, FRCSC at the American Urological Association (AUA) Annual Meeting- May 16 - 21, 2014 - Orlando, Florida USA

University of Montreal Hospital Centers, Montreal, Quebec Canada

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe